RxDoctor Payments Data

Balakrishna Ragoor, MD

Family Medicine · Monroeville, PANPI 1568436152

Payments from drug & device makers

$12,730in general payments, 2019–2025

Across 448 payments — averaging $28.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$893
  • AstraZeneca$828
  • Lilly USA, LLC$761
  • Johnson & Johnson$711
  • plus $7K from 33 others

What the payments were for

  • Travel & lodging$4373%
  • Food & beverage$12,17896%
  • Education$1161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,730 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$9,858
Medicare patients
53
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$38,753
OzempicSemaglutide18$38,691
XareltoRivaroxaban27$30,248
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$27,940
RexultiBrexpiprazole12$16,536
EliquisApixaban15$12,791
Spiriva HandihalerTiotropium Bromide18$11,505
Janumet XrSitagliptin Phos/Metformin Hcl17$7,406
Famotidine73$4,979
VascepaIcosapent Ethyl11$2,979
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,160
Atorvastatin Calcium150$1,938
Gabapentin111$1,762
Levothyroxine Sodium160$1,728
Rosuvastatin Calcium95$1,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$296$38,75332 claims
Novo NordiskOzempic$893$38,69118 claims
Johnson & JohnsonXarelto$711$30,24827 claims
GSKTrelegy Ellipta$1,161$27,94027 claims
Otsuka America Pharmaceutical, Inc.Rexulti$14$16,53612 claims
PfizerEliquis$658$12,79115 claims
MerckJanumet Xr$469$7,40617 claims
AbbVieSynthroid$1,720$1,14313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Monroeville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →